dentition defect
Conditions
Interventions
A1:Trapezoidal flap
A2:Rectangular flap
B1:proximo-central vertical incision angle-shaped flap
B2:distal-central vertical incision angle-shaped flap
C1:Sharp separation of periosteum
C2 :Blunt separation of periosteum
Sponsors
The Second Affiliated Hospital of Anhui Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. absence of any systemic disease that may impair implant wound healing; 2. recruitment to the study was limited to subjects aged = 18 years with a standardized health questionnaire score of 1 or 2; 3. appropriate periodontal health (only patients with PD < 5 mm; probing bleeding score and whole mouth plaque score < 20% were included to minimize the occurrence of biological complications after the procedure); 4. missing maxillary anterior teeth and presence of adjacent natural teeth; 5. other conditions related to post-extraction implant parameters include. a Presence of more than 4 mm of apical bone for initial stabilization; b Loss of buccal bone plate not exceeding 3 mm and horizontal bone gain not greater than 3 mm; c The absence of chronic periapical lesions that predispose to significant bone loss; d Presence of 2 mm of keratinized gingiva; 6. Voluntary participation and signing of the appropriate informed consent form; 7. Good patient compliance and ability to review as required.
Exclusion criteria
Exclusion criteria: 1. medically compromised subjects (ASA Class III-V) (American Society of Anesthesiologists surgical risk classification of patients); 2. general contraindications to implant therapy or adjuvant surgery (e.g., immunodeficiency, advanced systemic disease, corticosteroid medication); 3. Bone defects due to invasive, malignant bone tumors and treatments or diseases that may affect bone conversion or metabolism of bone or non-mineralized tissue (e.g., bisphosphonates or local radiation therapy); 4. Patients who are not eligible for GBR surgery or dental implant placement; 5. Heavy smokers (more than 10 cigarettes per day) during the same period; 6. Participation in other clinical trials within 3 months prior to the start of the study; 7. patients with severe cardiac, hepatic, or renal insufficiency (cardiac function = Class II, glutamic acid aminotransferase AST greater than twice the upper limit of normal, serum creatinine greater than the upper limit of normal); patients with diabetes mellitus that is poorly controlled (fasting blood glucose = 8.0 mmol/L even after medication control); 8. Mental anomalies, no behavioral autonomy; allergic patients, pregnant women or breastfeeding and those who plan to become pregnant within six months; 9. Patients who can not follow the requirements of follow-up lost visits.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean blood flow velocity;Maximum blood flow velocity; | — |
Secondary
| Measure | Time frame |
|---|---|
| S/D;pulsatility index;resistance index; | — |
Countries
China
Contacts
Public ContactRong Xia
The Second Affiliated Hospital of Anhui Medical University
Outcome results
None listed